Print

Hurel Corporation Appoints EMD Millipore Executive Iwona Kelley as Chief Business Officer  
4/23/2013 12:50:39 PM

North Brunswick, NJ, April 23, 2013 -- Hurel Corporation, (“Hurel”), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of Iwona Kelley, M.A., as Chief Business Officer. Ms. Kelley joins Hurel from EMD Millipore, and will be responsible for leading Hurel’s business, marketing strategy and client operations as the Company prepares for the commercial launch of its HurelStatic and HurelFlow products, which together improve the predictive reliability and over-all efficiency of pre-clinical drug development, reporting to Hurel CEO Robert Freedman.

At EMD Millipore, Ms. Kelley served as Biosciences Division District Manager, responsible for serving the life sciences communities in the North East United States, including the Boston/Cambridge bioplex. During her sixteen-year career with the Millipore family of companies, she held positions of progressively increasing authority for sales, domestic and international sales management, marketing strategy, and customer relations. Ms. Kelley began her career at Upstate Biotechnology, moving to Serologicals Corporation when Serologicals acquired Upstate in 2004. Her Millipore career began when Millipore acquired Serologicals in 2007, and continued when EMD, a subsidiary of Merck KGaA, the global chemical concern headquartered in Darmstadt, Germany, acquired Millipore in 2010.

“Iwona Kelley has put together a remarkable record of business development over the course of her extensive career,” said Hurel CEO Robert Freedman. “By staying really attuned to the needs of her customers, Iwona has demonstrated her talent for achieving rapid sales growth, exceeding sales targets and, in multiple instances, successfully launching first-to-market instrumentation, reagents, and software used in the Late Discovery and Pre-clinical Development stages of drug development. We are fortunate to have her at Hurel.”

Ms. Kelley’s broad product portfolios have included proprietary cell-based assays and analyzers, kinase panels, stem cells, flow cytometry instrumentation, and multiplex protein assay instrumentation, among many others. She received her Masters’ Degree in Biology from Harvard University and holds a Bachelors’ Degree in Biology from Holy Cross.

Ms. Kelley will remain based in Boston.

About Hurel

Hurel Corporation, based in North Brunswick, NJ and Beverly Hills, CA, is a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms that are used by major pharmaceutical research organizations in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products.


//-->